Company Profile: Healthscope Ltd (ASX: HSO) is a leading private healthcare provider with operations across Australia, New Zealand, Malaysia, Singapore and Vietnam. The group has many hospitals and medical centers for providing pathology diagnostics services. In Australia, it has 44 hospitals. The group also has a market leading international pathology operations across other regions. The group’s business was acquired by a consortium of funds, advised and managed by TPG and The Carlyle Group, which post delisting and a subsequent period of growth, again got listed on ASX in 2014. The group since then has also established various skin cancer clinics and breast diagnostic clinic in Australia.
Start discussion with value Investors for ASX Stock Market Investment and Opinion.
Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s
Those phrases have become increasingly common as marijuana legalization spreads.
Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500. Click here for your FREE Report